----

----

**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

**FORM      10-QSB**

| x | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934 |
|---|-----------------------------------------------------------------------------------------------------------------|

**For      the quarterly period ended June 30, 2007**

| o | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE                ACT |
|---|-----------------------------------------------------------------------------------------------|

**Medical      International Technology, Inc.**

| **Colorado**                                                                  | **84-1509950**                                   |
|-------------------------------------------------------------------------------|--------------------------------------------------|
| (State                or other jurisdiction of incorporation or organization) | (IRS                Employer Identification No.) |

**1872      Beaulac, **

**Ville      Saint-Laurent**

**Montreal,      Quebec, Canada H4R 2E7**

**(514)      339-9355**

----

**Transitional      Small Business Disclosure Format (check one):  Yes o  No x**

----

**Medical        International Technology, Inc.**

**Quarterly        Financial Report**

**Index**

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | **Page**Number                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| **PART                  I. FINANCIAL INFORMATION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  1. Consolidated Financial Statements**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| Consolidated                  Balance Sheet, June 30, 2007                  (unaudited)                                                                                                            | **4**                         |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| Consolidated                  Statements of Operations,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |     **6** |
| Three                  and Nine months ended June 30, 2007 and 2006 (unaudited)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| Consolidated                  Statements of Cash Flows                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |     **7** |
| Three                  and Nine months ended June 30, 2007 and 2006 (unaudited)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| Consolidated                  Statements of Comprehensive Loss                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |     **8** |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| Consolidated                  Statement of Stockholders’ (Deficit)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |     **9** |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| Notes                  to Unaudited Consolidated Financial Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   **10**            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  2. Management's Discussion and Analysis of Financial Condition                  and Plan of                  Operations**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | **13**                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  3. Controls and Procedures**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | **15**                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Part                  II. OTHER INFORMATION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  1. Legal                  Proceedings                                                      **                                                                                                                                                                                                                                                                                                                                                       | **15**                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  2. Unregistered Sales of Equity Securities and Use of                  Proceeds**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | **  15**            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  3. Defaults upon Senior Securities**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | **  17**            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  4. Submission of Matters to a Vote of Security                  Holders**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | **17**                        |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  5. Other Information**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | **  17**            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **Item                  6. Exhibits and Reports on Form 8-K**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | **  17**            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                          |
| **SIGNATURES                                **                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | **18**                        |

----

**PART        I.  FINANCIAL INFORMATION**

**ITEM        1.  Financial Statements**

----

----

| **Medical                  International Technology, Inc.** | **    Quarterly                  Financial Report** |
|-------------------------------------------------------------|-------------------------------------------------------------------------|

**CONSOLIDATED        BALANCE SHEET**

|                                                                                          |   | **June                  30,                  2007** |        |    | **September                  30, 2006** |   |
|-----------------------------------------------------------------------------------------------|--------|-----------------------------------------------------|-------------|---------|-----------------------------------------|--------|
|                                                                                          |   | (Unaudited)                                         |        |    | (Unaudited)                             |   |
| **Assets**                                                                                    |   |                                                |        |    |                                    |   |
| **    Current                  Assets**                                   |   |                                                |        |    |                                    |   |
|                        Cash and cash equivalents                     |   | $                                                   | 1,127       |    |                                    | $      | 2,920 |   |
|                        Accounts receivable                           |   |                                                | 5,012       |    |                                    |   | 19,244 |   |
|                        Inventories                                   |   |                                                | 140,385     |    |                                    |   | 78,822 |   |
|                        Research credit receivable                    |   |                                                | 124,354     |    |                                    |   | 182,630 |   |
|                        Prepaid expenses                              |   |                                                | 60,643      |    |                                    |   | 5,368 |   |
|                                                                                          |   |                                                |        |    |                                    |   |   |   |
| **                   Total Current Assets**                                              |   |                                                | 331,521     |    |                                    |   | 288,984 |   |
|                                                                                          |   |                                                |        |    |                                    |   |   |   |
| **Property                  and Equipment**                                                   |   |                                                |        |    |                                    |   |   |   |
|     Tooling                  and machinery                                |   |                                                | 225,175     |    |                                    |   | 225,175 |   |
|     Furniture                  and                  office equipment      |   |                                                | 133,010     |    |                                    |   | 59,372 |   |
|     Leasehold                  improvements                               |   |                                                | 22,163      |    |                                    |   | 22,163 |   |
|                                                                                          |   |                                                | 380,348     |    |                                    |   | 306,710 |   |
|                                                                                          |   |                                                |        |    |                                    |   |   |   |
|     Less                  accumulated depreciation                        |   |                                                | (231,950    | )  |                                    |   | (199,090 | )  |
|                                                                                          |   |                                                | 148,398     |    |                                    |   | 107,620 |   |
| **Other                  Assets**                                                             |   |                                                |        |    |                                    |   |   |   |
|     Patents                  (net accumulated amortization of $348, $466) |   |                                                | 1,216       |    |                                    |   | 1,564 |   |
|     Intangible                  asset                                     |   |                                                | 131,382     |    |                                    |   | - |   |
|                                                                                          |   |                                                |        |    |                                    |   |   |   |
|                                                                                          |   |                                                | 132,598     |    |                                    |   | 1,564 |   |
|                                                                                          |   |                                                |        |    |                                    |   |   |   |
| **    Total                  Assets**                                     |   | **$**                                               | **612,517** |    |                                    | **$**  | **398,168** |   |
|                                                                                          |   |                                                |        |    |                                    |   |   |   |

----

| **Medical                  International Technology, Inc.** | **    Quarterly                  Financial Report** |
|-------------------------------------------------------------|-------------------------------------------------------------------------|

**CONSOLIDATED        BALANCE SHEET**

|                                                                             |   | **June                  30, 2007** |        |   | **September                  30, 2006** |   |
|----------------------------------------------------------------------------------|--------|------------------------------------|-------------|--------|-----------------------------------------|--------|
|                                                                             |   | (Unaudited)                        |        |   | (Audited)                               |   |
| **Liabilities                  and Stockholders' (Deficit)**                     |   |                               |        |   |                                    |   |
| **Current                  Liabilities**                                         |   |                               |        |   |                                    |   |
|     Unearned                  income                         |   | $                                  | 89,314      |   |                                    | $      | 57,558 |   |
|     Accounts                  payable and accrued expenses   |   |                               | 492,275     |   |                                    |   | 420,356 |   |
|     Accounts                  payable - related parties      |   |                               | 321,936     |   |                                    |   | 221,844 |   |
|                                                                             |   |                               |        |   |                                    |   |   |   |
| **Total                  Liabilities**                                           |   |                               | 903,525     |   |                                    |   | 699,758 |   |
|                                                                             |   |                               |        |   |                                    |   |   |   |
| **Stockholders'                  (Deficit)**                                     |   |                               |        |   |                                    |   |   |   |
| Preferred                  stock, $.0001 par value; 3,000,000 shares authorized; |   |                               |        |   |                                    |   |   |   |
| None                  issued and outstanding as of June 30, 2007                 |   |                               |        |   |                                    |   |   |   |
|                                                                             |   |                               |        |   |                                    |   |   |   |
| Common                  stock, $.0001 par value; 100,000,000 shares authorized;  |   |                               |        |   |                                    |   |   |   |
| Issued                  and outstanding 18,184,197 shares as of June 30, 2007    |   |                               | 1,819       |   |                                    |   | 1,086 |   |
|                                                                             |   |                               |        |   |                                    |   |   |   |
| Additional                  paid-in capital                                      |   |                               | 6,395,446   |   |                                    |   | 5,786,600 |   |
| Retained                  deficit                                                |   |                               | (6,672,152  | )      |                                    |   | (6,073,155 | ) |
| Other                  comprehensive income (loss)                               |   |                               | (16,121     | )      |                                    |   | (16,121 | ) |
|                                                                             |   |                               |        |   |                                    |   |   |   |
| **Total                  Stockholders' (Deficit)**                               |   |                               | (291,008    | )      |                                    |   | (301,590 | ) |
|                                                                             |   |                               |        |   |                                    |   |   |   |
|                                                                             |   |                               |        |   |                                    |   |   |   |
| **Total                  Liabilities and Stockholders' (Deficit)**               |   | **$**                              | **612,517** |   |                                    | **$**  | **398,168** |   |
|                                                                             |   |                               |        |   |                                    |   |   |   |

----

| **Medical                  International Technology, Inc.** | **    Quarterly                  Financial Report** |
|-------------------------------------------------------------|-------------------------------------------------------------------------|

**Consolidated        Statements of Operations**

|                                                           |   | **For                  the Three-Months Ended** |       |    | **For                  the Nine-Months Ended** |   |
|----------------------------------------------------------------|--------|-------------------------------------------------|------------|---------|------------------------------------------------|--------|
|                                                           |   | **June                  30, 2007**              |       |    | **June                  30, 2007**             |   |
|                                                           |   | 2007                                            |       |    | 2006                                           |   |   | 2007 |   |   | 2006 |   |
|                                                           |   | (Unaudited)                                     |       |    | (Unaudited)                                    |   |   | (Unaudited) |   |   | (Unaudited) |   |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |
| Sales                                                          |   | $                                               | 43,020     |    |                                           | $      | 99,333 |   |   | $ | 150,630 |   |   | $ | 192,574 |   |
| Cost                  of sales                                 |   |                                            | 5778       |    |                                           |   | 48,285 |   |   |   | 58,151 |   |   |   | 101,813 |   |
|  Gross                    profit                          |   |                                            | 37,242     |    |                                           |   | 51,048 |   |   |   | 92,479 |   |   |   | 90,761 |   |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
| Research                    and development costs              |   |                                            | 68,097     |    |                                           |   | 60,657 |   |   |   | 126,255 |   |   |   | 256,202 |   |
| Selling,                  general, and administrative expenses |   |                                            | 136,343    |    |                                           |   | 89,501 |   |   |   | 508,407 |   |   |   | 1,049,304 |   |
|                                                           |   |                                            | 204,440    |    |                                           |   | 150,158 |   |   |   | 634,662 |   |   |   | 1,305,506 |   |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
| Net                    loss from operations                    |   |                                            | (167,198   | )       |                                           |   | (99,110 | ) |   |   | (542,184 | ) |   |   | (1,214,745 | ) |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
| Other                    Income (Expense)                      |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
| Interest                  income                               |   |                                            | ---        |    |                                           |   | --- |   |   |   | --- |   |   |   | 688 |   |
| Interest                    expense                            |   |                                            | (45,991    | )       |                                           |   | (5,873 | ) |   |   | (56,813 | ) |   |   | (24,013 | ) |
|                                                           |   |                                            | (45,991    | )  |                                           |   | (5,873 | ) |   |   | (56,813 | ) |   |   | (23,325 | ) |
| Net                    Loss                                    |   | $                                               | (213,189   | )       |                                           | $      | (104,983 | ) |   | $ | (598,997 | ) |   | $ | (1,238,070 | ) |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
| Basic                    weighted average shares outstanding   |   |                                            | 18,184,197 |    |                                           |   | 7,806,081 |   |   |   | 18,184,197 |   |   |   | 7,806,081 |   |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
| Basic                    (loss) per share                      |   | $                                               | (0.012     | )       |                                           | $      | (0.013 | ) |   | $ | (0.03 | ) |   | $ | (0.159 | ) |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |
|                                                           |   |                                            |       |    |                                           |   |   |   |   |   |   |   |   |   |   |   |

----

| **Medical                    International Technology, Inc.** | **    Quarterly                    Financial Report** |
|---------------------------------------------------------------|---------------------------------------------------------------------------|

**CONSOLIDATED        STATEMENTS OF CASH FLOWS**

| **Cash                  Flows from Operating Activities**                                               |   |   |     |   |   |   |
|---------------------------------------------------------------------------------------------------------|--------|--------|----------|--------|--------|--------|
|     Net                  Loss                                                       |   | $      | (598,997 | )      |   | $      | (1,238,070 | ) |
|     Adjustments                  to                  reconcile net loss to net cash |   |   |     |   |   |   |   |   |
|     Used                  in                  operating activities:                 |   |   |     |   |   |   |   |   |
|                        Depreciation and amortization expense                   |   |   | 33,208   |   |   |   | 33,760 |   |
|                        Common stock issued for consulting and legal services   |   |   | 369,559  |   |   |   | 237,176 |   |
|                        Common stock issued for acquisition of SCANVIEW         |   |   | 175,000  |   |   |   |   |   |
|                        Common stock issued for debts                           |   |   | -        |   |   |   | 241,999 |   |
|                                                                                                    |   |   | (21,230  | )      |   |   | (725,135 | ) |
| Increase                  (Decrease) in Assets                                                          |   |   |     |   |   |   |   |   |
|     (Increase)                  in                  accounts receivable             |   |   | 14,232   |   |   |   | 20,641 |   |
|     (Increase)                  decrease in inventories                             |   |   | (61,563  | )      |   |   | (50,916 | ) |
|     (Increase)                  decrease in research tax credit receivable          |   |   | 58,276   |   |   |   | (56,014 | ) |
|     (Increase)                  decrease in prepaid expenses                        |   |   | (55,275  | )      |   |   | (15,649 | ) |
|     Increase                  (Decrease) in Liabilities                             |   |   |     |   |   |   |   |   |
|     Increase                  (decrease) in unearned income                         |   |   | 31,756   |   |   |   | (51,185 | ) |
|     Increase                  (decrease) in accounts payable and accrued expenses   |   |   | 71,919   |   |   |   | (372,479 | ) |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **    Net                  Cash Used in Operating Activities**                      |   |   | 38,115   |   |   |   | (1,250,737 | ) |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **Cash                  Flows from Investing Activities**                                               |   |   |     |   |   |   |   |   |
|     Equipment                  acquisition                                          |   |   | (73,638  |   |   |   | (22,630 | ) |
|     Intangible                  asset                                               |   |   | (131,382 | )      |   |   | - |   |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **    Net                  cash used in investing activities**                      |   |   | (205,020 | )      |   |   | (22,630 | ) |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **Cash                  Flows from Financing Activities**                                               |   |   |     |   |   |   |   |   |
|     Gross                  proceeds from private offering                           |   |   | 65,020   |   |   |   | 1,506,005 |   |
|     Reduction                  in                  amounts due to related parties   |   |   | 100,092  |   |   |   | (38,373 | ) |
|     Principal                  reduction on small business loan                     |   |   | -        |   |   |   | (13,372 | ) |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **    Net                  Cash Provided by Financing Activities**                  |   |   | 165,112  |   |   |   | 1,454,260 |   |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **Effect                  of exchange rates on cash**                                                   |   |   | -        |   |   |   | (40,781 | )  |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **Net                  Increase in Cash and Cash Equivalents**                                          |   |   | (1,793   | )      |   |   | 140,112 |   |
| **Beginning                  Balance - Cash and Cash Equivalents**                                      |   |   | 2,920    |   |   |   | 5,874 |   |
| **Ending                  Balance - Cash and Cash Equivalents**                                         |   | $      | 1,127    |   |   |   | 145,986 |   |
|                                                                                                    |   |   |     |   |   |   |   |   |
|                                                                                                    |   |   |     |   |   |   |   |   |
| **Supplemental                  Information:**                                                          |   |   |     |   |   |   |   |   |
| **    Cash                  Paid For**:                                             |   |   |     |   |   |   |   |   |
|                        Interest Expenses                                       |   | $      | 56,812   |   |   | $      | 24,013 |   |
|                                                                                                    |   |   |     |   |   |   |   |   |

----

| **Medical                      International Technology, Inc.** | **    Quarterly                      Financial Report** |
|-----------------------------------------------------------------|-----------------------------------------------------------------------------|

**CONSOLIDATED        STATEMENTS OF COMPREHENSIVE LOSS**

|                                                                                                                        |   | **Third                  quarter ending** |         |   | **For                  the year ended** |
|-----------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------|--------------|--------|-----------------------------------------|
|                                                                                                                        |   | **30-Jun-07**                             |         |   | **September                  30,**      |
|                                                                                                                        |   | **2007**                                  |         |   | **2006**                                |   |   | **2005** |
| **Net                  loss**                                                                                               |   | $                                         | (598,997     | )      |                                    | $ | (1,509,663 | ) |   | $ | (772,154 | ) |
|     Other                  comprehensive income (loss)                                                  |   |                                      |         |   |                                    |   |   |   |   |   |   |   |
|                              Foreign currency translation adjustment |   |                                      | -            |   |                                    |   | 20,203 |   |   |   | 49,723 |   |
|                                                                                                                        |   |                                      |         |   |                                    |   |   |   |   |   |   |   |
| **Net                  comprehensive income (loss)**                                                                        |   | **$**                                     | **(598,997** | **)**  |                                    | **$** | **(1,489,430** | **)** |   | **$** | **(722,431** | **)** |
|                                                                                                                        |   |                                      |         |   |                                    |   |   |   |   |   |   |   |

----

| **Medical                    International Technology, Inc.** | **    Quarterly                    Financial Report** |
|---------------------------------------------------------------|---------------------------------------------------------------------------|

**CONSOLIDATED        STATEMENT OF STOCKHOLDERS’ (DEFICIT)**

|                                                               |   |                              |           |   |                         |   |      | **Additional** |   |   |          |   |
|--------------------------------------------------------------------|--------|-----------------------------------|----------------|--------|------------------------------|--------|-----------|----------------|--------|--------|---------------|--------|
|                                                               |   | **Common                  Stock** |           |   | **Paid                  in** |   |      |           |   |
|                                                               |   | **Shares**                        |           |   | **Amount**                   |   |      | **Capital**    |   |   | **Deficit**   |   |
| **Balance                  – September 30, 2006**            |   |                              | **10,867,737** |   |                         | **$**  | **1,086** |           |   | **$**  | **5,786,600** |   |   | **$** | **(6,073,155** | **)** |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
| Shares                    issued for services                      |   |                              | 779,400        |   |                         |   | 78        |           |   |   | 163,596       |   |   |   | - |   |
| Shares                  issued private placements                  |   |                              | 72,000         |   |                         |   | 7         |           |   |   | 14,993        |   |   |   | - |   |
| Net                    loss for the period ended December 31, 2006 |   |                              | -              |   |                         |   | -         |           |   |   | -             |   |   |   | (277,470 | )  |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
| **Balance                    –December 31, 2006**            |   |                              | **11,719,137** |   |                         | **$**  | **1,171** |           |   | **$**  | **5,965,189** |   |   | **$** | **(6,350,625** | **)** |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
| Shares                  issued for services                        |   |                              | 43,750         |   |                         |   | 6         |           |   |   | 10,200        |   |   |   | - |   |
| Shares                    issued private placements                |   |                              | 200,000        |   |                         |   | 20        |           |   |   | 50,000        |   |   |   | - |   |
| Net                  loss for the period ended March 31, 2007      |   |                              | -              |   |                         |   | -         |           |   |   | -             |   |   |   | (108,338 | ) |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
| **Balance                  –March 31, 2007**                 |   |                              | **11,962,887** |   |                         | **$**  | **1,197** |           |   | **$**  | **6,025,389** |   |   | **$** | **(6,458,963** | **)** |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
| Shares                    issued for services                      |   |                              | 3,721,310      |   |                         |   | 372       |           |   |   | 195,307       |   |   |   | - |   |
| Shares                  issued private placements                  |   |                              | -              |   |                         |   | -         |           |   |   | -             |   |   |   | - |   |
| Shares                    issued acquisition of SCANVIEW           |   |                              | 2,500,000      |   |                         |   | 250       |           |   |   | 174,750       |   |   |   | - |   |
| Net                  loss for the period ended June 30, 2007       |   |                              | -              |   |                         |   | -         |           |   |   | -             |   |   |   | (213,189 | ) |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |
| **Balance                    –June 30, 2007**                |   |                              | **18,184,197** |   |                         | **$**  | **1,819** |           |   | **$**  | **6,395,446** |   |   | **$** | **(6,672,152** | **)** |
|                                                               |   |                              |           |   |                         |   |      |           |   |   |          |   |   |   |   |   |

----

| **Medical                      International Technology, Inc.** | **    Quarterly                      Financial Report** |
|-----------------------------------------------------------------|-----------------------------------------------------------------------------|

**Notes        to Unaudited Consolidated Financial Statements**

**Note        1 – Basis of Presentation**

**Interim        Financial Statements**

**Note        2 – Summary of Significant Accounting Policies**

**Principles        of consolidation**

**Foreign        Currency Translations**

** **

**Allowance        for Doubtful Accounts**

**Inventories**

**Property        and Equipment**

**Intangible        assets**

**Net        Loss per Share**

----

| **Medical                        International Technology, Inc.** | **    Quarterly                        Financial Report** |
|-------------------------------------------------------------------|-------------------------------------------------------------------------------|

**Notes        to Unaudited Consolidated Financial Statements**

**Cash        and Cash Equivalents**

**Use        of Estimates**

**Long-Lived        Assets**

**Reclassification**

**Income        Taxes**

**Fair        Value of Financial        Instruments**

**Revenue        Recognition**

**Note        3 - Intangible Assets**

----

| **Medical                        International Technology, Inc.** | **    Quarterly                        Financial Report** |
|-------------------------------------------------------------------|-------------------------------------------------------------------------------|

**Notes        to Unaudited Consolidated Financial Statements**

**Note        4 - Stock Activity**

**Issuance        of Common Stock**

**Note        5 - Related Party Transactions**

|   | Note                  6 – Acquisiton of Scanview |
|--------|--------------------------------------------------------|

----

**Item        2.     Management's Discussion and Analysis of        Financial Condition and Plan of Operations**

**Results        of Operations for the Nine-Months ended June 30, 2007 and        2006**

**Liquidity        and Capital Resources**

**Management        Plan of Operations**

----

**Product        Development**

----

**Forward-Looking        Statements**

**Item        3. Controls and Procedures**

**Part        II OTHER INFORMATION**

**Item        1. Legal Proceedings**

| 1.   | Two                  suppliers, Farimetal, Inc. and Outils Diacarb have instituted legal                  proceedings against the company in the approximate amount of $26,200.                  The                  company also instituted counter claims against those suppliers                  in the                  approximate amount of $33,750. The actions are before the Court                  of the                  Province of Quebec and are scheduled for May 4th,                  2006 and                  April 19th,                  2006. These                  subcontractors provided services that did not meet MIT specifications                  which resulted scrapping many components and delaying deliveries                  to                  Japan.  Neither the possible outcome nor the amount of possible                  settlement can be foreseen in these proceedings. The ultimate resolution                  of these matters is not expected to have a material adverse effect                  on the                  Company’s financial position. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Item        2. Unregistered Sales of Equity Securities and Use of        Proceeds**

----

----

**Item        3. Defaults upon Senior Securities**

**Item        4. Submission of Matters to a Vote of Security Holders**

**Item        5. Other information**

**Item        6.                      Exhibits        and Reports on Form 8-K**

----

**SIGNATURES**

|                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                 | Medical                      International Technology, Inc.                                                                                                                                                                                                                                                                                                                                                                                |
|                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| August                      30, 2007 | By:/s/Karim                      Menassa,                      President                                                            |
|                                 | Karim                      Menassa, President and Principal Executive Officer                                                                                                                                                                                                                                                                                                                                                              |
|                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| August                      30, 2007 | By:/s/Michel                      Bayouk,                      Secretary                                                            |
|                                 | Michel                      Bayouk, Secretary and Principal Accounting                      Officer                                                                                                                                                                                                                                                                                                                                        |